A research team at UCSF has developed an antiviral aerosol spray, dubbed AeroNabs, that they report has the ability to ward off coronoavirus infection by blocking the ACE2 receptor pathway. The protective molecule is synthesized in a lab by imprinting the genetic blueprints of the most potent known antibodies against SARS-CoV-2 into e. coli and yeast, which churn out the nanobodies needed for the compound. Going one step further, the researchers combined some of the most protective nanobodies they were studying, which they say led to the discovery of "one linked triple nanobody [that] was 200,000 times more potent than any of the single nanobodies alone."

While the original study is focused on a nasal spray application, the team is in talks with partners to begin clinical trials and eventual commercialization with other forms of the product, including placement in air filtration units. There is even a possibility it may have a use in those already infected with coronavirus, which they hope to study as soon as they secure the necessary funding.

Read the full article in The Sacramento Bee by clicking here.